Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

Kamashev, D.E., Vitoux, D. & de Thé, H. PML/RARA-RXR oligomers mediate retinoid- and rexinoid- /cAMP in APL cell differentiation. J. Exp. Med. 199, 1163–1174 (2004). 10.1084/jem.20032226

[2]

van Wageningen, S. et al. Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RAR{alpha}. Blood 111, 1634–1643 (2008). 10.1182/blood-2007-04-081125

[3]

Melnick, A. & Licht, J.D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93, 3167–3215 (1999). 10.1182/blood.v93.10.3167.410k44_3167_3215

[4]

Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079–1082 (2002). 10.1126/science.1065173

[5]

Zhu, J. et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7, 143–153 (2005). 10.1016/j.ccr.2005.01.005

[6]

Zhou, J. et al. Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. Proc. Natl. Acad. Sci. USA 103, 9238–9243 (2006). 10.1073/pnas.0603324103

[7]

Villa, R. et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11, 513–525 (2007). 10.1016/j.ccr.2007.04.009

[8]

Zhu, J. et al. RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 12, 23–35 (2007). 10.1016/j.ccr.2007.06.004

[9]

Zeisig, B.B. et al. Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell 12, 36–51 (2007). 10.1016/j.ccr.2007.06.006

[10]

Quignon, F., Chen, Z. & de Thé, H. Retinoic acid and arsenic: towards oncogene targeted treatments of acute promyelocytic leukaemia. Biochim. Biophys. Acta 1333, M53–M61 (1997).

[11]

Zhu, J., Lallemand-Breitenbach, V. & de The, H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 20, 7257–7265 (2001). 10.1038/sj.onc.1204852

[12]

Wang, Z.Y. & Chen, Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111, 2505–2515 (2008). 10.1182/blood-2007-07-102798

[13]

Muindi, J. et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 79, 299–303 (1992). 10.1182/blood.v79.2.299.299

[14]

Nervi, C. et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood 92, 2244–2251 (1998).

[15]

Zhu, J. et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RAR alpha) and oncogenic RAR alpha fusion proteins. Proc. Natl. Acad. Sci. USA 96, 14807–14812 (1999). 10.1073/pnas.96.26.14807

[16]

Lane, A.A. & Ley, T.J. Neutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in mice. Cell 115, 305–318 (2003). 10.1016/s0092-8674(03)00852-3

[17]

vom Baur, E. et al. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J. 15, 110–124 (1996). 10.1002/j.1460-2075.1996.tb00339.x

[18]

Lallemand-Breitenbach, V. et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As(2)O(3)-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193, 1361–1372 (2001). 10.1084/jem.193.12.1361

[19]

Mann, K.K. et al. Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation. J. Clin. Invest. 115, 2924–2933 (2005). 10.1172/jci23628

[20]

Zhu, J. et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94, 3978–3983 (1997). 10.1073/pnas.94.8.3978

[21]

Lallemand-Breitenbach, V. et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10, 547–555 (2008). 10.1038/ncb1717

[22]

Hayakawa, F. & Privalsky, M.L. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5, 389–401 (2004). 10.1016/s1535-6108(04)00082-0

[23]

Lallemand-Breitenbach, V. et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189, 1043–1052 (1999). 10.1084/jem.189.7.1043

[24]

Rego, E.M., He, L.Z., Warrell, R.P., Jr., Wang, Z.G. & Pandolfi, P.P. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc. Natl. Acad. Sci. USA 97, 10173–10178 (2000). 10.1073/pnas.180290497

[25]

Westervelt, P. et al. Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 99, 9468–9473 (2002). 10.1073/pnas.132657799

[26]

Lallemand-Breitenbach, V., Zhu, J., Kogan, S., Chen, Z. & de The, H. Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia. Nat. Rev. Cancer 5, 821–827 (2005). 10.1038/nrc1719

[27]

Shen, Z.X. et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 101, 5328–5335 (2004). 10.1073/pnas.0400053101

[28]

Estey, E. et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107, 3469–3473 (2006). 10.1182/blood-2005-10-4006

[29]

Shao, W. et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARalpha protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 90, 124–133 (1998). 10.1093/jnci/90.2.124

[30]

Ruchaud, S. et al. Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc. Natl. Acad. Sci. USA 91, 8428–8432 (1994). 10.1073/pnas.91.18.8428

[31]

Guillemin, M.C. et al. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J. Exp. Med. 196, 1373–1380 (2002). 10.1084/jem.20021129

[32]

Altucci, L. et al. Rexinoid-triggered differentiation and tumours selective apoptosis of AML by protein kinase-A-mediated de-subordination of RXR. Cancer Res. 65, 8754–8765 (2005). 10.1158/0008-5472.can-04-3569

[33]

Gaillard, E. et al. Phosphorylation by PKA potentiates retinoic acid receptor alpha activity by means of increasing interaction with and phosphorylation by cyclin H/cdk7. Proc. Natl. Acad. Sci. USA 103, 9548–9553 (2006). 10.1073/pnas.0509717103

[34]

Wang, J.C. & Dick, J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494–501 (2005). 10.1016/j.tcb.2005.07.004

[35]

Zheng, X. et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 92, 323–331 (2007). 10.3324/haematol.10541

[36]

He, L.Z. et al. Two critical hits for promyelocytic leukemia. Mol. Cell 6, 1131–1141 (2000). 10.1016/s1097-2765(00)00111-8

[37]

He, L.-Z. et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat. Genet. 18, 126–135 (1998). 10.1038/ng0298-126

[38]

Parrella, E. et al. Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways. J. Biol. Chem. 279, 42026–42040 (2004). 10.1074/jbc.m406530200

[39]

Zhu, J., Chen, Z., Lallemand-Breitenbach, V. & de Thé, H. How acute promyelocytic leukemia revived arsenic. Nat. Rev. Cancer 2, 705–713 (2002). 10.1038/nrc887

[40]

Turhan, A.G. et al. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood 85, 2154–2161 (1995). 10.1182/blood.v85.8.2154.bloodjournal8582154

[41]

Zheng, P.Z. et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 102, 7653–7658 (2005). 10.1073/pnas.0502825102

[42]

Role of SUMO-Interacting Motif in Daxx SUMO Modification, Subnuclear Localization, and Repression of Sumoylated Transcription Factors

Ding-Yen Lin, Yen-Sung Huang, Jen-Chong Jeng et al.

Molecular Cell 2006 10.1016/j.molcel.2006.10.019

[43]

Ito, K. et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072–1078 (2008). 10.1038/nature07016

[44]

Tsimberidou, A.M. et al. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk. Lymphoma 47, 1062–1068 (2006). 10.1080/10428190500463932

[45]

Chen, G.Q. et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 10, 825–828 (1996).

[46]

Koken, M.H.M. et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene 18, 1113–1118 (1999). 10.1038/sj.onc.1202414

[47]

Costoya, J.A. et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat. Genet. 36, 653–659 (2004). 10.1038/ng1367

[48]

Khetchoumian, K. et al. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat. Genet. 39, 1500–1506 (2007). 10.1038/ng.2007.15

[49]

Purton, L.E. et al. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J. Exp. Med. 203, 1283–1293 (2006). 10.1084/jem.20052105

[50]

Matthay, K.K. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341, 1165–1173 (1999). 10.1056/nejm199910143411601

Cited By

312

UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability

Jonathan M. Tsai, Jacob D. Aguirre · 2023

Molecular Cell

Acute promyelocytic leukemia (APL): a review of the literature

Joaquin J. Jimenez, Ravinder S. Chale · 2020

Oncotarget

Nucleostemin silencing induces differentiation and potentiates all- trans -retinoic acid effects in human acute promyelocytic leukemia NB4 cells via autophagy

Aila Fakhimahmadi, Farinaz Nazmi · 2017

Leukemia Research

PML-RARα and Its Phosphorylation Regulate PML Oligomerization and HIPK2 Stability

Yutaka Shima, Yuki Honma · 2013

Cancer Research

Endoplasmic reticulum calcium pumps and cancer

Atousa Arbabian, Jean-Philippe Brouland · 2011

BioFactors

Retinoids regulate stem cell differentiation

Lorraine J. Gudas, John A. Wagner · 2010

Journal of Cellular Physiology

Metrics

312

Citations

50

References

Details

Published: Nov 23, 2008
Vol/Issue: 14(12)
Pages: 1333-1342
License: View

Authors

R

Rihab Nasr

M

Marie-Claude Guillemin

Macarena Robledo-Sarmiento

V

Valérie Lallemand-Breitenbach

Chinese University of Hong Kong

H

Hugues de Thé

Cite This Article

Rihab Nasr, Marie-Claude Guillemin, Omar Ferhi, et al. (2008). Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nature Medicine, 14(12), 1333-1342. https://doi.org/10.1038/nm.1891

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

You May Also Like